Health Highlights: IPOs, Pharma Deals, and Medical Advancements

This summary provides a snapshot of current health news, including IPO pricing by biotech startups, Sanofi's potential sale of its consumer health business, HMI Medical's acquisition in Singapore, a halted multiple sclerosis drug study by Denali-Sanofi, and Bayer's legal challenges. It also covers UN's polio campaign concerns in Gaza, ADHD statistics, Novo Nordisk's strategic moves in India, a bird flu case in California, and Medicare plan ratings.

In recent healthcare news, U.S. biotech startups, including Upstream Bio, have successfully priced their IPOs amid a rising trend in healthcare listings. Upstream Bio, focusing on respiratory treatment development, raised $255 million through its IPO, confirming robust market interest.

French pharmaceutical giant Sanofi announced negotiations to sell a 50% stake in its consumer health division to Clayton Dubilier & Rice, following reports of an estimated 15 billion euros deal. In Asia, HMI Medical has acquired a significant stake in Advanced Urology Associates, further expanding its presence in specialist healthcare.

Meanwhile, Denali Therapeutics and its partner Sanofi have halted a mid-stage drug trial for multiple sclerosis after it failed key objectives. Additionally, Bayer faces a court order to pay $78 million in a Roundup case, highlighting ongoing legal challenges for the company. The UN has also expressed concerns over the impact of Gaza's evacuation on its polio vaccination efforts.

(With inputs from agencies.)